Stuttgart Region
Global pharma executive bridging Clinical Development (Ph I–III) and Global Medical Affairs to accelerate value creation in cardiometabolic and related diseases (metabolism, obesity, diabetes, cardiology). Board-certified in Internal Medicine, combining deep clinical expertise with a business mindset to translate science into differentiated patient and product impact. I lead end-to-end across the R&D–Medical interface: clinical and medical strategy, portfolio/pipeline prioritization, evidence generation (RWE/HEOR), KOL engagement, scientific communications, governance, and launch readiness. I have contributed to and led launches across cardiology, nephrology, hepatology and metabolism, aligning cross-functional stakeholders to deliver strong execution in complex global matrix environments. Leadership & scope - Worldwide responsibilities across regions | Phase I–III - Leading and developing teams of ~50 in matrix organizations - Known for structured problem-solving, stakeholder alignment, and building high-performing teams with optimism and pace Focus areas - Cardiometabolic disease (obesity, diabetes, metabolic disorders, cardiology) with additional cross-therapy experience in nephrology and hepatology.
Executive Group Director (n-1), R&D & Global Medical Affairs Wörwag Pharma Group Group-level executive reporting directly to the CEO and member of the Executive Committee, with full accountability for R&D and Global Medical Affairs across the Wörwag Pharma Group. End-to-end ownership of the global innovation, development, and medical strategy, covering the full product lifecycle from early innovation through clinical development to post-launch medical evidence Leadership of 40 FTEs across global functions: - Global Innovation Office - Global Clinical Development - Global Product Development - Global Medical Affairs Executive responsibility for a diversified therapeutic portfolio including metabolism (obesity, diabetes, liver health), immunology, neurology, and bone health Driving group strategy, portfolio prioritization, and long-term value creation at Executive Committee level
Leading Senior Director within the Lilly/BI Alliance - Responsibility for strategy in heart failure, diabetes, chronic kidney disease - Medical Launch Lead for heart failure (HFrEF, HFmrEF/HFpEF), chronic kidney disease - Responsibility for crossfunctional planning and execution of brand plans - Strong crosfunctional working style leveraging the full Alliance potential - Representative of Lilly at EU public-private research program IMI-SOPHIA - Representative of Lilly at the German Heart Foundation (Deutsche Herzstiftung)
Leading Medical Advisor within the Alliance with BI - Medical responsibilty in strategic and operational functions for heart failure, diabetes, chronic kidney disease - Medical Launch Lead for HFrEF - Lilly Germany medical strategy Lead for brand plan
Consultant within the department of Diabetology, Endocrinology and Nephrology - Responsibility for diabetes and endocrinology within the inpatient and outpatient unit - Regular service in emergency dialysis centre Clinical investigator for several studies (e.g.): - planning and execution of longitudinal RWE studiy - TUEDID study - Application of clamp technology to examine human metabolism in experimental settings
several assignments in: - Internal Medicine, Diabetology and Endocrinoloy - Pulmology - Cardiology - Intensive Care Unit